Skip to main content
PMC home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1994 Oct;38(10):2469–2470. doi: 10.1128/aac.38.10.2469

In vitro activities of enoxacin, enrofloxacin, sparfloxacin, and ciprofloxacin against Escherichia coli strains isolated from diarrheic lambs and kids.

D Cid 1, S Piriz 1, J A Ruiz-Santa-Quiteria 1, J Valle 1, S Garcia 1, S Vadillo 1, R de la Fuente 1
PMCID: PMC284765  PMID: 7840590

Abstract

The in vitro activities of four fluoroquinolone compounds were tested against 92 Escherichia coli strains of ovine and caprine origin under aerobic and anaerobic incubation conditions. The four fluoroquinolones proved to be highly effective against the E. coli isolates tested. When bacteria were cultured anaerobically, at least fourfold increases in the MICs of enoxacin for the strains occurred and no detectable changes in enrofloxacin, sparfloxacin, and ciprofloxacin MICs occurred.

Full text

PDF
2469

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Barry A. L., Fuchs P. C. In vitro activities of sparfloxacin, tosufloxacin, ciprofloxacin, and fleroxacin. Antimicrob Agents Chemother. 1991 May;35(5):955–960. doi: 10.1128/aac.35.5.955. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Boerema J. B., Olthof B. J., van Saene H. K. Effects of norfloxacin on the faecal flora in patients with complicated urinary tract infections. Scand J Infect Dis Suppl. 1986;48:27–31. [PubMed] [Google Scholar]
  3. Bryan J. P., Waters C., Sheffield J., Krieg R. E., Perine P. L., Wagner K. In vitro activities of tosufloxacin, temafloxacin, and A-56620 against pathogens of diarrhea. Antimicrob Agents Chemother. 1990 Feb;34(2):368–370. doi: 10.1128/aac.34.2.368. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Ericsson C. D., Johnson P. C., Dupont H. L., Morgan D. R., Bitsura J. A., de la Cabada F. J. Ciprofloxacin or trimethoprim-sulfamethoxazole as initial therapy for travelers' diarrhea. A placebo-controlled, randomized trial. Ann Intern Med. 1987 Feb;106(2):216–220. doi: 10.7326/0003-4819-106-2-216. [DOI] [PubMed] [Google Scholar]
  5. Goossens H., De Mol P., Coignau H., Levy J., Grados O., Ghysels G., Innocent H., Butzler J. P. Comparative in vitro activities of aztreonam, ciprofloxacin, norfloxacin, ofloxacin, HR 810 (a new cephalosporin), RU28965 (a new macrolide), and other agents against enteropathogens. Antimicrob Agents Chemother. 1985 Mar;27(3):388–392. doi: 10.1128/aac.27.3.388. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Kojima T., Inoue M., Mitsuhashi S. In vitro activity of AT-4140 against clinical bacterial isolates. Antimicrob Agents Chemother. 1989 Nov;33(11):1980–1988. doi: 10.1128/aac.33.11.1980. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Pecquet S., Andremont A., Tancrède C. Selective antimicrobial modulation of the intestinal tract by norfloxacin in human volunteers and in gnotobiotic mice associated with a human fecal flora. Antimicrob Agents Chemother. 1986 Jun;29(6):1047–1052. doi: 10.1128/aac.29.6.1047. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Pichler H. E., Diridl G., Stickler K., Wolf D. Clinical efficacy of ciprofloxacin compared with placebo in bacterial diarrhea. Am J Med. 1987 Apr 27;82(4A):329–332. [PubMed] [Google Scholar]
  9. Piddock L. J. New quinolones and gram-positive bacteria. Antimicrob Agents Chemother. 1994 Feb;38(2):163–169. doi: 10.1128/aac.38.2.163. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Rao D. S., Parfitt A. M., Villanueva A. R., Dorman P. J., Kleerekoper M. Hypophosphatemic osteomalacia and adult Fanconi syndrome due to light-chain nephropathy. Another form of oncogenous osteomalacia. Am J Med. 1987 Feb;82(2):333–338. doi: 10.1016/0002-9343(87)90081-7. [DOI] [PubMed] [Google Scholar]
  11. Segreti J., Nelson J. A., Goodman L. J., Kaplan R. L., Trenholme G. M. In vitro activities of lomefloxacin and temafloxacin against pathogens causing diarrhea. Antimicrob Agents Chemother. 1989 Aug;33(8):1385–1387. doi: 10.1128/aac.33.8.1385. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Smith S. M., Eng R. H., Cherubin C. E. Conditions affecting the results of susceptibility testing for the quinolone compounds. Chemotherapy. 1988;34(4):308–314. doi: 10.1159/000238584. [DOI] [PubMed] [Google Scholar]
  13. Visser M. R., Rozenberg-Arska M., Beumer H., Hoepelman I. M., Verhoef J. Comparative in vitro antibacterial activity of sparfloxacin (AT-4140; RP 64206), a new quinolone. Antimicrob Agents Chemother. 1991 May;35(5):858–868. doi: 10.1128/aac.35.5.858. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Wolfson J. S., Hooper D. C. Fluoroquinolone antimicrobial agents. Clin Microbiol Rev. 1989 Oct;2(4):378–424. doi: 10.1128/cmr.2.4.378. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES